Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 3/20 | 0.39 |
| ▸ | FES | P07332 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 5/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.39 |
| ▸ | CDC42BPA | Q5VT25 | 5/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.39 |
| ▸ | PRKACA | P17612 | 4/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.39 |
| ▸ | GSK3A | P49840 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20095478 | 0.89 | HDAC1 (0.48) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| SCHEMBL20095306 | 0.88 | HDAC1 (0.47) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| SCHEMBL27008595 | 0.79 | MAPKAPK2 (0.44) | HDAC1MAPKAPK2FLT4FESFGFR1 | |
| SCHEMBL20095660 | 0.78 | HDAC1 (0.61) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| SCHEMBL12077917 | 0.76 | NAMPT (0.53) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| SCHEMBL12077957 | 0.76 | NAMPT (0.53) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| SCHEMBL12077914 | 0.76 | NAMPT (0.53) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| SCHEMBL20095662 | 0.75 | HDAC1 (0.61) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| SCHEMBL2552281 | 0.75 | NAMPT (0.56) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| SCHEMBL21461996 | 0.74 | GPR119 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293554-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | SEAGEN INC (US) | 2024-09-05 | — | — | US | disclosed |
| US-11931414-B2 | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates | SEAGEN INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | SEATTLE GENETICS, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | SEATTLE GENETICS, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| CN-110799217-A | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates | 西雅图基因公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20190314519-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEATTLE GENETICS, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190314519-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEATTLE GENETICS, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| WO-2018075600-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEATTLE GENETICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931414-B2 | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates | NAMPT, NNMT, NADK | HDAC1 152/4885HDAC3 175/4885HDAC2 215/4885 |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | NAMPT, NAPRT, NNMT | HDAC1 409/4885HDAC3 430/4885HDAC2 431/4885 |
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | NAMPT, NNMT, NADK | HDAC1 152/4885HDAC3 175/4885HDAC2 215/4885 |
| US-20240293554-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | NAMPT, NNMT, NADK | HDAC1 152/4885HDAC3 175/4885HDAC2 215/4885 |
| US-20190314519-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | NAMPT, NME4, NNMT | HDAC1 179/4885HDAC3 208/4885HDAC2 283/4885 |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | NAMPT, NME4, NNMT | HDAC1 179/4885HDAC3 208/4885HDAC2 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.